Text size :

Breast cancer, Botticelli (Umberto I): “With genomic tests -40% chemotherapy prescriptions”

ADNKRONOS

November 17, 2026

Rome, Nov 17. (Adnkronos Health) – “Genomic tests allow us to understand gene-level mutations, and in breast cancer, these become particularly important because they enable us to define the risk of recurrence, or disease relapse”.

“The introduction of genomic tests has allowed us to reduce chemotherapy prescriptions by at least 40%. They were reimbursed, but today they are also included in the Lea, essential levels of assistance. This brings us into the perspective of equity, continuity of the care pathway, but above all, the message is that biology becomes an integral part of the care pathway for our patients.” This was stated by Andrea Botticelli, director of the Uoc Oncology at Policlinico Umberto I in Rome, at the XXVIII National Congress of the Italian Association of Medical Oncology (Aiom), held from November 13 to 15 in Rome.

Jiji Press

Related

Page TOP